Autolymphocyte therapy

Drug Profile

Autolymphocyte therapy

Alternative Names: ALT

Latest Information Update: 08 Jan 2001

Price : $50

At a glance

  • Originator Cytogen Corporation
  • Class Cell therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Malignant melanoma; Prostate cancer; Renal cancer

Most Recent Events

  • 08 Jan 2001 Discontinued-III for Renal cancer in USA (Infusion)
  • 08 Jan 2001 Discontinued-I for Renal cancer in Netherlands (Infusion)
  • 08 Jan 2001 Discontinued-I for Prostate cancer (Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top